NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Avenue Biosciences

Avenue Biosciences

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://www.avenuebiosciences.com/

Last Round

Seed

Jan 12, 2026

Total Funding Raised

$14.36M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Avenue Biosciences is a biotechnology company that provides a protein engineering platform powered by machine learning to optimize protein expression and production for biopharmaceutical applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

protein engineeringbiologics developmentsignal peptidesynthetic biologybioprocess engineeringtherapeutic proteinsprotein expressiondrug discoverysecretory pathwayAI drug discoverymachine learning platformCDMOcontract developmentbiotech R&Din silico design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avenue Biosciences Comps

Public and private peers based on sector, stage, and business model.

Avenue Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Avenue Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 12, 2026
SeedOct 22, 2024
SeedJan 16, 2024

Key People

Founding team and executive leadership

Tero-Pekka Alastalo

Chief Executive Officer

Executive Team

Veli-Pekka Jaakola

Chief Technology Officer

Executive Team

Avenue Biosciences Investors

Notable investors and investment history

Avenue Biosciences investors
InvestorRounds
TesiSeed
University of HelsinkiSeed
BalnordSeed
InventureSeed
Voima VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 12, 2026

    $5.7M raised in Seed round.

  • May 20, 2025

    Veli-Pekka Jaakola appointed as new CTO.

Avenue Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Avenue Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Avenue Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range22
Year Founded2023
Last FundingJan 12, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.